326 related articles for article (PubMed ID: 36315425)
21. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
23. Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance.
Cui S; Guo Y; Li J; Bian W; Wu W; Zhang W; Zheng Q; Guan H; Wang J; Niu J
Ann Hematol; 2024 May; 103(5):1665-1673. PubMed ID: 38326481
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
25. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
[TBL] [Abstract][Full Text] [Related]
26. Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.
Chen YT; Valent ET; van Beers EH; Kuiper R; Oliva S; Haferlach T; Chng WJ; van Vliet MH; Sonneveld P; Larocca A
Int J Lab Hematol; 2022 Feb; 44(1):127-134. PubMed ID: 34448362
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
28. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
[TBL] [Abstract][Full Text] [Related]
30. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.
Li JR; Arsang-Jang S; Cheng Y; Sun F; D'Souza A; Dhakal B; Hari P; Huang Q; Auer P; Li Y; Urrutia R; Zhan F; Shaughnessy JD; Janz S; Dong J; Cheng C
Blood Cancer J; 2024 Mar; 14(1):38. PubMed ID: 38443358
[TBL] [Abstract][Full Text] [Related]
31. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
32. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
33. Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.
Abe Y; Sunami K; Yamashita T; Ueda M; Takamatsu H; Narita K; Kobayashi H; Kitadate A; Takeuchi M; Matsue K
Oncotarget; 2019 Jan; 10(5):595-605. PubMed ID: 30728910
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
35. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
37. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and
Cho HJ; Jung SH; Jo JC; Lee YJ; Yoon SE; Park SS; Kim DY; Shin HJ; Mun YC; Yi JH; Kim HJ; Kim DJ; Lee HS; Bae SH; Hong CM; Jeong SY; Min JJ; Sohn SK; Min CK; Kim K; Lee JJ; Moon JH;
Blood Cancer J; 2021 Dec; 11(12):190. PubMed ID: 34853295
[TBL] [Abstract][Full Text] [Related]
38. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.
Swamydas M; Murphy EV; Ignatz-Hoover JJ; Malek E; Driscoll JJ
J Hematol Oncol; 2022 Feb; 15(1):17. PubMed ID: 35172851
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
[No Abstract] [Full Text] [Related]
40. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
Guillerey C; Nakamura K; Vuckovic S; Hill GR; Smyth MJ
Cell Mol Life Sci; 2016 Apr; 73(8):1569-89. PubMed ID: 26801219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
